Cartalax is a synthetic tripeptide (Ala-Glu-Asp) developed by Vladimir Khavinson as part of the bioregulatory peptide series. It is designed to normalize cartilage and connective tissue function through epigenetic gene regulation. Evidence is limited to Russian literature.
2 independent Janoshik purity tests cover Cartalax across 2 vendors. Results range from 99.5% to 99.7%.
Category: Bioregulator / Research. Evidence rating: D (animal/preclinical only).
Clinical status: Research-only
Cartalax regulates gene expression in chondrocytes through chromatin remodeling at tissue-specific promoters. It promotes cartilage ECM synthesis and provides anti-inflammatory modulation in joints.
Safety considerations: Minimal data outside Russian literature.
Reviewed by the PeptideAtlas Editorial Team.
| Production method | synthetic |
|---|---|
| Anti-doping status | not-listed |
| Vendor | Best tested purity |
|---|---|
| Modern Peptides | 99.7% |
| Cocer Peptides | 99.5% |
Related peptides: Ovagen.
A series of short synthetic peptides (2-4 amino acids) developed by Russian gerontologist Vladimir Khavinson. They are theorized to regulate tissue-specific gene expression at sub-pharmacological doses. Most evidence is published in Russian journals without independent Western replication.
Cartalax is a bioregulator tripeptide (Ala-Glu-Asp) from the Khavinson peptide family, researched for cartilage maintenance and musculoskeletal health. Part of the Russian bioregulator peptide tradition.
CARTALAX has been studied for: Cartilage support, Musculoskeletal health, Anti-aging potential, Connective tissue maintenance. Khavinson bioregulator peptide. Limited Western clinical data.
Bioregulator peptide that may influence gene expression related to cartilage and connective tissue maintenance and repair.
Coverage on this site: Epithalon Research: Telomerase Activation and Longevity Effects.
Independent lab results for Cartalax: Cartalax 20mg — Independent Lab Test Results.